Analytical Spectral Devices, Inc.

Analytical Spectral Devices (ASD) will debut its RxSpec 700Z portable drug anti-counterfeiting device at the upcoming IFPAC show in Baltimore, Jan. 28-31. The system enables real-time drug verification that will prevent harmful counterfeit drugs from getting into the hands of consumers.

The RxSpec 700Z is a portable version of the patented technology that ASD introduced into mail order pharmacies two years ago. It fits the FDA’s call for applying new technologies to distinguish legitimate drugs from counterfeits and will be a useful tool for pharmaceutical companies, customs and border control agencies, and anybody in the drug distribution chain concerned with drug counterfeiting.

"Before RxSpec, drugs had to be taken to a lab and tested to see if they were counterfeit,” explained ASD’s Director of Business Development Michael Lands. “This new device verifies drugs in real-time, helping the pharmaceutical industry cut costs by reducing testing time and lowering liability risks, and ultimately protecting corporate revenues.”

Using Near-Infrared (NIR) spectroscopic technology, the device provides a glimpse of what new drug safety technologies can be applied throughout the pharmaceutical industry’s entire process, from the manufacturing plant to the retail pharmacy.

Company Information

    Analytical Spectral Devices

  • 5335 Sterling Drive, Suite A
  • Boulder, Colo. 80301 (see map)
  • Phone: (303) 444-6522
  • Fax: (303) 444-6825
  • email: mktg@asdi.com
  • Website: www.asdi.com